Agilent Technologies Inc. lowered its annual revenue and profit guidance Wednesday even as it logged stronger-than-expected adjusted earnings for its latest quarter, propelled by sales growth in two out of three business segments. About Agilent Technologies Agilent Technologies Inc. Average recommendation stands as “OVERWEIGHT” with consensus analysis of “16” Analysts. The stock was sold at an average price of $44.07, for a total value of $232,072.62.
Advertisement
According to FactSet data, the stock has received different ratings from Financial Analysts. They now have a Dollars 47 price target on the stock. Agilent Technologies, Inc. (NYSE:A) PEG ratio is at 2.50.
05/17/2016 – Agilent Technologies, Inc. had its “buy” rating reiterated by analysts at Evercore ISI. After the session opened at $5.10, the stock’s price hit the top of $ 5.19 while it touched a low of $ 4.60.
02/17/2016 – Agilent Technologies, Inc. had its “outperform” rating reiterated by analysts at Robert W. Baird. The stock is now trading up its SMA 50 of $46.50. 1 analysts have rated the company as a “Hold”. They now have a Dollars 39 price target on the stock. “0” said as “SELL” recommendations and “0” suggested “UNDERWEIGHT” rating.
This Little Known Stocks Could Turn Every $10,000 into $42,749!
11/03/2015 – Agilent Technologies, Inc. had its “neutral” rating reiterated by analysts at UBS.
Price Momentum: Despite the -0.33% drop in value, the stock’s new closing price reflects a -0.7% fall in price from company’s one year high of $48.62. The company’s distance from 52 week high is -0.70% and current price is above +46.98% from 52 week low. Company has a market cap of $15,768 M. Agilent Technologies, Inc. (NYSE:A) 52-week high is $48.63 and the 52-week low is $33.12. The Company’s life sciences and applied markets business segment brings together the Company’s analytical laboratory instrumentation and informatics.
Advertisement
Third-quarter revenue of $504 million from Agilent’s Life Sciences and Applied Markets Group (LSAG) reduced 1 percent year over year (down 2 percent on a core basis (2)), in line with expectations. Its life sciences and applied markets business segment offers instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level. Its diagnostics and genomics business segment includes the reagent partnership, pathology, companion diagnostics, genomics and the nucleic acid solutions businesses. Visit MarketWatch.com for more information on this news.
